Overview

Pharmacokinetics and Pharmacodynamics of BCT194 in Psoriatic Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetics and pharmacodynamics of BCT194 in psoriatic patients to better understand the skin penetration of topically applied BCT194.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals